OpenAI takes on Google with new AI designed to speed drug discovery
This image was generated by AI and may not depict real events.
OpenAI has released an early version of its GPT-Rosalind AI model to accelerate drug discovery, joining Google and other tech companies in the field. The model is designed to help researchers analyze large datasets and turn scientific studies into healthcare applications.
OpenAI has launched GPT-Rosalind, an AI model designed to speed up drug discovery. The model is intended for life sciences research and will be available to some business customers, including Amgen and Moderna. GPT-Rosalind can help researchers analyze large volumes of data and turn scientific studies into healthcare applications. OpenAI hopes the model will act as a research partner, accelerating complex and time-intensive parts of the scientific process. The company is working to ensure safe use, including 'high-precision flags' for bioweapons-related indicators. Shares of companies involved in drug discovery fell sharply on the news.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.